Loading [MathJax]/jax/output/SVG/jax.js
Review

Soluble Fas ligand, soluble Fas receptor, and decoy receptor 3 as disease biomarkers for clinical applications: A review

  • Received: 19 January 2022 Revised: 19 February 2022 Accepted: 22 February 2022 Published: 28 March 2022
  • Soluble Fas ligand (sFasL, sCD95L) and its specific soluble binders, soluble Fas receptor (sFas, sCD95) and decoy receptor 3 (DcR3), have been investigated as possible clinical biomarkers in many serious diseases. The present review aimed to provide an overview of the current state of this medically promising research by extensively examining the relevant literature. The summarized results of the survey are presented after classification into six categories according to the type of targeted disease. To date, the studies have been mainly devoted to the diagnosis of disease severity states and prognosis of treatments about various types of cancers and autoimmune diseases represented by autoimmune lymphoproliferative syndrome and systemic lupus erythematosus, because these important life-threatening or intractable diseases were suggested to be most relevant to the impairment of apoptotic cell death-inducing systems, including the Fas receptor-mediated signaling system, and the mechanisms responsible for their onset. However, various more general inflammation-related diseases, including, but not limited to, other autoimmune and allergic diseases (e.g., rheumatoid arthritis and atopic asthma), infectious diseases (e.g., sepsis and chronic hepatitis), cardiovascular system-specific disorders (e.g., acute coronary syndromes and heart failure) as well as other diseases specific to the renal, hepatic, and respiratory systems, etc., have also been targeted as important fields of research. The data obtained so far demonstrated that sFas, sFasL, and DcR3 possess significant potential in the assessment of various disease states, which can contribute to the development of therapeutic interventions. Although further studies in various relevant fields are essential, it is expected that clinical translation of sFas, sFasL, and DcR3 into practical biomarkers will contribute to effective treatments of a wide variety of diseases.

    Citation: Michiro Muraki. Soluble Fas ligand, soluble Fas receptor, and decoy receptor 3 as disease biomarkers for clinical applications: A review[J]. AIMS Medical Science, 2022, 9(2): 98-267. doi: 10.3934/medsci.2022009

    Related Papers:

    [1] Nichaphat Patanarapeelert, Thanin Sitthiwiratthame . On nonlocal fractional symmetric Hanh integral boundary value problems for fractional symmetric Hahn integrodifference equation. AIMS Mathematics, 2020, 5(4): 3556-3572. doi: 10.3934/math.2020231
    [2] Varaporn Wattanakejorn, Sotiris K. Ntouyas, Thanin Sitthiwirattham . On a boundary value problem for fractional Hahn integro-difference equations with four-point fractional integral boundary conditions. AIMS Mathematics, 2022, 7(1): 632-650. doi: 10.3934/math.2022040
    [3] Ugyen Samdrup Tshering, Ekkarath Thailert, Sotiris K. Ntouyas . Existence and stability results for a coupled system of Hilfer-Hadamard sequential fractional differential equations with multi-point fractional integral boundary conditions. AIMS Mathematics, 2024, 9(9): 25849-25878. doi: 10.3934/math.20241263
    [4] Weerawat Sudsutad, Chatthai Thaiprayoon, Sotiris K. Ntouyas . Existence and stability results for ψ-Hilfer fractional integro-differential equation with mixed nonlocal boundary conditions. AIMS Mathematics, 2021, 6(4): 4119-4141. doi: 10.3934/math.2021244
    [5] Subramanian Muthaiah, Dumitru Baleanu, Nandha Gopal Thangaraj . Existence and Hyers-Ulam type stability results for nonlinear coupled system of Caputo-Hadamard type fractional differential equations. AIMS Mathematics, 2021, 6(1): 168-194. doi: 10.3934/math.2021012
    [6] Hasanen A. Hammad, Hassen Aydi, Manuel De la Sen . The existence and stability results of multi-order boundary value problems involving Riemann-Liouville fractional operators. AIMS Mathematics, 2023, 8(5): 11325-11349. doi: 10.3934/math.2023574
    [7] Bashir Ahmad, Manal Alnahdi, Sotiris K. Ntouyas, Ahmed Alsaedi . On a mixed nonlinear boundary value problem with the right Caputo fractional derivative and multipoint closed boundary conditions. AIMS Mathematics, 2023, 8(5): 11709-11726. doi: 10.3934/math.2023593
    [8] Omar Choucha, Abdelkader Amara, Sina Etemad, Shahram Rezapour, Delfim F. M. Torres, Thongchai Botmart . On the Ulam-Hyers-Rassias stability of two structures of discrete fractional three-point boundary value problems: Existence theory. AIMS Mathematics, 2023, 8(1): 1455-1474. doi: 10.3934/math.2023073
    [9] Ahmed Alsaedi, Fawziah M. Alotaibi, Bashir Ahmad . Analysis of nonlinear coupled Caputo fractional differential equations with boundary conditions in terms of sum and difference of the governing functions. AIMS Mathematics, 2022, 7(5): 8314-8329. doi: 10.3934/math.2022463
    [10] Supriya Kumar Paul, Lakshmi Narayan Mishra . Stability analysis through the Bielecki metric to nonlinear fractional integral equations of n-product operators. AIMS Mathematics, 2024, 9(4): 7770-7790. doi: 10.3934/math.2024377
  • Soluble Fas ligand (sFasL, sCD95L) and its specific soluble binders, soluble Fas receptor (sFas, sCD95) and decoy receptor 3 (DcR3), have been investigated as possible clinical biomarkers in many serious diseases. The present review aimed to provide an overview of the current state of this medically promising research by extensively examining the relevant literature. The summarized results of the survey are presented after classification into six categories according to the type of targeted disease. To date, the studies have been mainly devoted to the diagnosis of disease severity states and prognosis of treatments about various types of cancers and autoimmune diseases represented by autoimmune lymphoproliferative syndrome and systemic lupus erythematosus, because these important life-threatening or intractable diseases were suggested to be most relevant to the impairment of apoptotic cell death-inducing systems, including the Fas receptor-mediated signaling system, and the mechanisms responsible for their onset. However, various more general inflammation-related diseases, including, but not limited to, other autoimmune and allergic diseases (e.g., rheumatoid arthritis and atopic asthma), infectious diseases (e.g., sepsis and chronic hepatitis), cardiovascular system-specific disorders (e.g., acute coronary syndromes and heart failure) as well as other diseases specific to the renal, hepatic, and respiratory systems, etc., have also been targeted as important fields of research. The data obtained so far demonstrated that sFas, sFasL, and DcR3 possess significant potential in the assessment of various disease states, which can contribute to the development of therapeutic interventions. Although further studies in various relevant fields are essential, it is expected that clinical translation of sFas, sFasL, and DcR3 into practical biomarkers will contribute to effective treatments of a wide variety of diseases.



    Abbreviations used in main text ACLF:

    Acute-on-chronic liver failure; 

    ACS:

    Acute coronary syndrome; 

    AD:

    Alzheimer's disease; 

    ADA:

    Adenosine deaminase; 

    ADPKD:

    Autosomal dominant polycystic kidney disease; 

    AGVHD:

    Acute graft-versus-host disease; 

    AHI:

    Apnea-hypopnea index; 

    AHSCT:

    Allogeneic hematopoietic stem cell transplantation; 

    AKI:

    Acute kidney injury; 

    ALT:

    Alanine aminotransferase; 

    ALPS:

    Autoimmune lymphoproliferative syndrome; 

    AMD:

    Age-related macular degeneration; 

    AMI:

    Acute myocardial infarction; 

    APACHE:

    Acute physiology and chronic health evaluation; 

    AR:

    Acute rejection; 

    ARDS:

    Acute respiratory distress syndrome; 

    AS:

    Ascites; 

    BLC:

    Bladder cancer; 

    BMI:

    Body-mass-index; 

    CABG:

    Coronary artery bypass grafting; 

    CAD:

    Coronary artery disease; 

    CB:

    Cord blood; 

    CCC:

    Coronary collateral circulation; 

    CHD:

    Coronary heart disease; 

    CIR:

    Cirrhosis; 

    CKD:

    Chronic kidney disease; 

    CLC-PH:

    Compensated liver cirrhosis accompanied with portal hypertension; 

    COPD:

    Chronic obstructive pulmonary disease; 

    COVID-19:

    SARS-CoV-2 virus; 

    CR:

    Clinical remission; 

    CRP:

    C-reactive protein; 

    CSF:

    Cerebrospinal fluid; 

    CVD:

    Cardiovascular disease; 

    DcR3:

    Decoy receptor 3; 

    DFL:

    Diabetic foot lesions; 

    DISC:

    Death-inducing signaling complex; 

    DM:

    Diabetes mellitus; 

    ECD:

    Extracellular domain; 

    eGFR:

    Estimated glomerular filtration rate; 

    EPO:

    Erythropoietin; 

    ESA:

    Erythropoietin-stimulating agent; 

    ESRD:

    End-Stage renal disease; 

    EVD:

    Ebora virus disease; 

    FADD:

    Fas-associating protein with death domain; 

    FasL:

    Fas ligand; 

    FL:

    Flare; 

    GD:

    Graves' disease; 

    GH:

    Graves' hyperthyroidism; 

    GIST:

    Gastrointestinal stromal carcinoma; 

    GO:

    Graves' ophthalmopathy; 

    Hb:

    Hemoglobin; 

    HBV:

    Hepatitis-B virus; 

    HCC:

    Hepatocellular cancer; 

    HCV:

    Hepatitis-C virus; 

    HD:

    Hemodialysis; 

    HDC:

    Hydrocephalus; 

    HF:

    Heart failure; 

    HFRS:

    Hemorrhagic fever with renal syndrome; 

    HIE:

    Hypoxic-ischemic encephalopathy; 

    HIV:

    Human immune-deficiency virus; 

    HNC:

    Head and neck cancer; 

    HRT:

    Hormone replacement therapy; 

    HYP:

    Hypertension; 

    IFN:

    Interferon; 

    IL:

    Interleukin; 

    IPH:

    Intraparenchymal hemorrhage; 

    IS:

    Ischemic stroke; 

    IUGR:

    Intrauterine growth restriction; 

    KD:

    Kawasaki disease; 

    LF:

    Liver fibrosis; 

    LN:

    Lupus nephritis; 

    MCI:

    Mild cognitive impairment; 

    MELD:

    Model for end-stage liver disease; 

    METS:

    Metabolic syndrome; 

    MS:

    Multiple sclerosis; 

    NAFLD:

    Nonalcoholic fatty liver disease; 

    NASH:

    Nonalcoholic steatohepatitis; 

    NH:

    Non-hemorrhagic; 

    NNAG:

    Nonagenarians; 

    Non-RS:

    Non-resolving subphenotype; 

    O2T:

    Oxygen-gas treatment; 

    PE:

    Pleural effusion; 

    PH:

    Post-hemorrhagic; 

    PKTR:

    Pediatric kidney transplant recipients; 

    PL:

    Plasma; 

    PMS:

    Postmenopausal syndrome; 

    PPCM:

    Peripartum cardiography; 

    PRC:

    Prostate cancer; 

    PRF:

    Preserved renal function; 

    PTE:

    Pulmonary thromboembolism; 

    PVL:

    Periventricular leukomalacia; 

    RA:

    Rheumatoid arthritis; 

    RCC:

    Renal cell cancer; 

    RRMS:

    Relapsing-remitting MS; 

    SAL:

    Saliva; 

    SCD:

    Sickle cell disease; 

    SF:

    Synovial fluid; 

    sFas:

    Soluble Fas receptor; 

    sFasL:

    Soluble Fas ligand; 

    SIRS:

    Systemic inflammatory response syndrome; 

    SJS:

    Stevens-Johnson syndrome; 

    SLE:

    Systemic lupus erythematosus; 

    SOFA:

    Sequential organ failure assessment; 

    SR:

    Serum; 

    STC:

    Stomach cancer; 

    TNF:

    Tumor necrosis factor; 

    SS:

    Sjögren's syndrome; 

    SUH:

    Subarachnoid hemorrhage; 

    T1DM:

    Type-1 DM; 

    T2DM:

    Type-2 DM; 

    T/AB:

    Tau protein/amyloid β 1-42 ratio; 

    TB:

    Tuberculosis; 

    TEN:

    Toxic epidermal necrolysis; 

    TRAb:

    Thyroid stimulating hormone receptor antibodies; 

    TEN:

    Toxic epidermal necrolysis; 

    VO2-max:

    Peak oxygen consumption; 

    VED:

    Vascular endothelial dysfunction; 

    WS:

    Werner syndrome; 

    %fat:

    Percent body fat; 

    Abbreviations used in Tables' columns for assay methods and statistical indices AUC:

    The area under the curve; 

    b:

    Regression coefficient; 

    Corr.:

    Correlation analysis; 

    C statistic:

    Concordance statistic; 

    CV:

    Cutoff value; 

    DDA:

    Double determinant immunoassay; 

    ELISA:

    Enzyme-linked immunosorbent assay; 

    HR:

    Hazard ratio; 

    Iqr:

    Interquartile range; 

    LC-ESI MS:

    Liquid chromatography-electrospray ionization mass-spectrometry method; 

    Md:

    Median; 

    Mn:

    Mean; 

    MPAA:

    Multiplex array assay; 

    nd:

    Not described; 

    ns:

    Not significant; 

    OR:

    Odds ratio; 

    p:

    Probability value; 

    PEA:

    Primer extension assay; 

    r:

    Pearson's correlation coefficient; 

    rs:

    Spearman's correlation coefficient; 

    r2:

    Determination coefficient; 

    Rg:

    (whole) Range; 

    ROC curve:

    Receiver operating characteristic curve; 

    RR:

    Risk ratio; 

    SD:

    Standard deviation; 

    SEM:

    Standard error of the mean; 

    WB:

    Western-blotting method; 

    95% CI:

    95% Confidential interval

    According to statistics from the World Health Organization (WHO), approximately 17.9 million people die from cardiovascular diseases every year [1]. Arrhythmia is a common clinical manifestation of cardiovascular diseases, and electrocardiogram (ECG) monitoring is an effective method for detecting and recording arrhythmias. Therefore, real-time and high-precision automatic ECG monitoring can effectively predict arrhythmias.

    Nowadays, traditional machine learning methods and deep learning-based methods are the most widely used for arrhythmia classification methods. Traditional machine learning methods are usually implemented for ECG classification using sample feature-based learning methods, such as support vector machine (SVM) [2], random forest [3], k-nearest neighbor classifier (k-NN) [4], decision tree [5], Bayesian classifier [6], etc. For example, Faziludeen and Sabiq [7] proposed a new method that utilizes Daubechies 4 wavelet decomposition for heartbeat feature selection, and 25 features were extracted from each heartbeat through wavelet analysis, and then SVM method was used to classify them. In addition, Li and Zhou [8] used the entropy of wavelet packet decomposition (WPD) coefficients as representative features and subsequently employed random forest (RF) for ECG classification. Venkatesan et al. [9] proposed an adaptive filter with the delay error normalized least mean squares (LMS) algorithm to address the issue of prolonged processing time for ECG signals, which achieved high speed and good classification performances. However, in these traditional machine learning methods, the classification performance often heavily depends on the quality of feature engineering, and the normal beat (N) and supraventricular premature beat (S) classes often represents similar wave form with similar features. Therefore, it is difficult to classify them accurately using conventional approaches.

    Among deep learning-based methods, one-dimensional convolutional neural network (1-D CNN) is widely used for the classification of cardiac arrhythmias. Acharya et al. [10] proposed a 9-layer deep convolutional neural network (CNN) which can successfully classified 5 different categories of ECG signals by eliminating high-frequency noise and data augmentation. Hannun et al. [11] conducted a comprehensive evaluation of end-to-end deep learning methods for ECG classification, and achieved high diagnostic performance similar to that of cardiologists. Mousavi and Afghah [12] proposed a novel and effective ECG-based automatic heartbeat classification method, which addresses the challenge of ECG data imbalance by utilizing a sequence-to-sequence deep learning method and an oversampling technique algorithm. Sabut et al. [13] proposed a deep neural network (DNN) approach based on mixed time-frequency features, which can enhance the diagnostic efficiency of ventricular tachycardia (VT) and ventricular fibrillation (VF). In addition, recurrent neural networks (RNN) [14] was a promising way to capture the forward and backward dependencies of time series. Lynn et al. [15] proposed a bidirectional gated recurrent unit (GRU) method to implement ECG classification effectively. Yildirim [16] proposed deep bidirectional long short-term memory (LSTM) networks and wavelet sequences for ECG classification, achieving good classification performances.

    Most ECG classification methods focused on the evaluation under an intra-patient assessment paradigm. This intra-patient evaluation paradigm often neglected the differences of ECG signals from different patients, thereby limiting its generalization ability. The inter-patient assessment, as used in the clinical application scenarios, often meets these problems such as data imbalance and inter-individual variability, which can deteriorate the classification accuracy and generalization capability of the model. To address the above issues, we propose a novelty method for ECG classification as following:

    1) A multi-path parallel deep convolutional neural network is proposed for arrhythmia classification by extracting the features of P wave, QRS wave group, and T wave simultaneously, and a global average RR interval is introduced to address the issue of data similarity between normal beat (N) and supraventricular premature beat (S).

    2) A weighted loss function has been developed to dynamically adjust weights based on the proportion of each class in the input batch, so as to overcome the data imbalance problem.

    3) Both intra-patient and inter-patient evaluation paradigms are used to validate the classification performances of the proposed method, and the experimental results showed that the proposed method can achieve the most accurate classification performances among these state-of-the-art methods.

    The rest of this paper is organized as follows: Section 2 introduces the ECG datasets and the proposed method. Section 3 outlines the experimental setup and comparison between the proposed method and state-of-the-art methods. Section 4 discusses the performance of the proposed model and conducts ablation experiments to verify the effectiveness of the model. Section 5 summarizes and looks forward to this paper.

    In this paper, the MIT-BIH arrhythmia database [17] is used to validate the proposed method for ECG classification. The MIT-BIH Arrhythmia Database is an open-source dataset provided by the Massachusetts Institute of Technology (MIT) and recommended by the Association for the Advancement of Medical Instrumentation (AAMI) [18]. It contains 48 dual-channel ECG records collected from 47 patients, with a duration of about half an hour. Each recording consisted of two leads (i.e., Leads Ⅰ and Ⅱ), sampled in the range of 10 mV per channel at a sampling frequency of 360 Hz, and each recording was individually annotated by two cardiologists (total 110,000 notes). In this paper, Lead Ⅱ (MLII) ECG datasets was used for training and testing the proposed method.

    According to the standards from AAMI, the beats of ECG signals can be categorized into five categories for the classification of arrhythmias, as shown in Table 1. Because AAMI defines the Q-type cardiac beat as an unknown category, which is for reference only and has no specific application value, in this paper, we primarily utilize the first four categories as experimental data.

    Table 1.  AAMI classification criteria for cardiac arrhythmias.
    AAMI heartbeat class N S V F Q
    MIT-BIH heartbeat types Normal beat Atrial premature beat Premature ventricular contraction Fusion of ventricular and normal beat Paced beat
    Left bundle branch block beat Aberrated atrial premature beat Ventricular escape beat Fusion of paced and normal beat
    Right bundle branch block beat Nodal (junctional) premature beat Unclassifiable beat
    Atrial escape beat Supraventricular premature beat
    Nodal (junctional) escape beat

     | Show Table
    DownLoad: CSV

    In this paper, intra-patient and inter-patient experiments are used to validate the classification performances of the proposed method. In the intra-patient evaluation approach, the training and testing sets are collected together with a total of 100,501 heartbeats from different patients, and the training and testing samples are partitioned based on heartbeats. Additionally, we utilize a 10-fold cross-validation method to validate the model. We divide all heartbeats into 10 equal parts, sequentially selecting 9 parts as the training set and the rest 1 part as the testing set. This process is repeated 10 times. However, there are some limitations to this evaluation method, because some heartbeat samples may come from the same patient in both the training and testing sets. In the inter-patient evaluation approach, we followed De Chazal et al. [19] definition of dataset partitions and divided it into DS1 and DS2 datasets, as shown in Table 2. Furthermore, DS1 was used for model training, while DS2 was used for model testing. In this scheme, different numerical identifiers represent different patients' ECG records. It fully accounts for individual diversity and can effectively evaluate the universality and robustness of the proposed method.

    Table 2.  ECG data sample division.
    Dataset ECG recording
    DS1 '101', '106', '108', '109', '112', '114', '115', '116', '118', '119', '122', '124', '201', '203', '205', '207', '208', '209', '215', '220', '223', '230'
    DS2 '100', '103', '105', '111', '113', '117', '121', '123', '200', '202', '210', '212', '213', '214', '219', '221', '222', '228', '231', '232', '233', '234'

     | Show Table
    DownLoad: CSV

    For a given ECG signal, the ECG preprocessing procedure includes as follows:

    1) ECG heartbeat segmentation. According to the annotations made by experts on the R-peak and heartbeat categories of the ECG signal, the R-peak position of each heartbeat in the data is obtained. Since the sampling frequency of the ECG acquisition equipment is 360 Hz, and the cardiac cycle is about 0.8 s, we use a fixed window of length 255 to capture the heartbeat waveform. For each heartbeat, we take the preceding 128 points and the following 127 points from the R peak as a sample.

    2) Eliminating data instability. Considering that wearing and taking off the instrument will cause severe heartbeat fluctuations, we removed the first 10 and last 10 heartbeats to ensure the stability of the heartbeat.

    The distribution of beats in different categories of the MIT-BIH arrhythmia database is presented in Table 3. It can be found that the heartbeat distribution of different categories is seriously imbalanced. Moreover, unbalanced data often leads to overfitting in categories with a large number of samples. Therefore, a dynamic weighted focal loss is proposed to address the data imbalance problem, which can adjust the weight dynamically using the number of heartbeats of different categories in the input batch.

    Table 3.  Beat distribution of different categories in the MIT-BIH arrhythmia database.
    Heart class DS1 DS2 Total
    N 45,490 43,885 89,375
    S 929 1822 2751
    V 3770 3196 6966
    F 412 388 800

     | Show Table
    DownLoad: CSV

    First, we define a label set Batch_labeli as show in Eq (1), representing X heartbeats contained in the i-th training batch, where yj denote the j-th beat label in Batch_labeli, yj{N,S,V,F}, and each category corresponds to a different one-hot encoding, such as N=[1,0,0,0], S=[0,1,0,0].

    Batch_labeli={y1,y2,y3,...,yX} (1)

    Therefore, we define the weight of the i-th batch as αi, as shown in Eq (2), assigning different weights based on the number of different categories in each batch. The larger the proportion of a certain category in each batch, the lower the weight obtained. In addition, the smaller the proportion, the greater the weight obtained, of which 0.05 is to prevent the weight from reaching 0.

    αi=XXi=1yi2+0.05 (2)

    In addition, the i-th batch weighted focal loss is defined as Li, as shown in Eq (3), where ˆy represents the predicted probability of each class and y is the one-hot encoding of the ground truth label.

    Li=αi(1ˆy)ylogˆy (3)

    When performing classification tasks, convolutional networks often struggle to learn the differences between N-class and S-class waveforms due to their wave similarities. Additionally, N-class data is much more abundant than S-class data, which can further degrade the generalization of model. However, compared to N-class data, S-class data typically exhibit incomplete compensatory intervals, indicating shorter forward RR intervals. The forward RR interval represents the time interval between the current heartbeat's R-wave and the R-wave of the previous heartbeat. Therefore, in this paper, we introduce RR intervals to assist the network in classification. The definition of the forward RR interval is illustrated in Eq (4), where i represents the i-th RR interval and j represents the j-th patient.

    RRj(i)=R(i)R(i1) (4)

    In this paper, we adopted an overall average normalization method, given that the ventricular beat rate varies among different patients, resulting in variable RR intervals. First, the average of all RR intervals for j-th patient is defined as RRaver,j, as shown in Eq (5). With j-th patient's RRaver,j as the standard for this patient, the forward RR interval divided by the patient's RRaver,j is defined as RRglobal,j(i). The RRglobal,j(i) represents the global average RR interval, as shown in Eq (6).

    RRaver,j=1NNi=0RRj(i) (5)
    RRglobal,j=RRj(i)RRaver,j (6)

    The global average normalization method standardizes RR intervals across different patients, facilitating data comparison. Additionally, due to the limited number of features, four transformations are used to expand the global average RR interval feature space, as defined in Eqs (7)–(10). In this study, five features (RRglobal,j(i), RR1, RR2, RR3, RR4) are used to train the network for ECG classification tasks.

    RR1=RRglobal,j(i)2 (7)
    RR2=eRRglobal,j(i) (8)
    RR3=eRRglobal,j(i)1 (9)
    RR4=ln(RRglobal,j(i)) (10)

    In order to present the data distribution more intuitively, we use Gaussian kernel density estimation to analyze the relationship between the global average RR interval and variants, as shown in Figure 1. In the figure, the horizontal axis represents the global average RR interval. The vertical axis represents the probability density of occurrence. Figure 1 illustrates that in both the training set and the testing set, the global average RR interval can make the N class and the S class be linearly separable.

    Figure 1.  Probability density distribution of the global mean RR interval for the training set and testing set.

    We propose a multi-path parallel deep convolutional neural network with strong generalization ability, as shown in Figure 2. The network is mainly composed of 20 convolutional layers, 20 activation function layers, 20 batch normalization layers [20], 8 dropout layers, 3 MaxPool layers, 2 fully connected layers, 1 LSTM layer, and 1 softmax layer. The following are details about the model structure.

    Figure 2.  Multi-path parallel deep convolutional neural network.

    Input: In this paper, we divided the ECG signal into 3 segments, each with a length of 85, and fed them into three identical parallel networks to extract the features of the P wave, QRS wave group, and T wave, respectively. Therefore, the network can focus on features extraction from different periods simultaneously. In addition, we adopted the global average RR interval feature and its four variants as the fourth input of the network to help the network perform classification. We use a convolutional network for feature extraction on this feature, mainly to increase the dimension of the feature, thereby increasing its weight in network decision-making and classification.

    Convolutional Blocks: In our network, we define the initial three layers as convolutional blocks for extracting initial features at different time periods. This module consists of a convolutional layer, a batch normalization layer, and a ReLU activation function layer. The convolutional layer consists of 16 convolutions with a kernel size of 5 × 1.

    Layer structure: Compared to the traditional convolutional neural network (CNN), the residual network achieves higher classification accuracy and overcomes the issue of information loss [21]. In this paper, we design a residual structure. The structure initially conducts feature extraction through 32 1-D convolutions with a convolution length of 5 × 1 and a stride of 1. Then, batch normalization is applied to the extracted features. The ReLU activation function is used to prevent gradient vanishing and saturation. Next, a dropout layer [22] randomly deactivates 20% of the neurons to prevent overfitting. Finally, feature extraction is performed again through 32 1-D convolutions with a convolution length of 7 × 1 and a stride of 1. The extracted features are then normalized and activated. It is worth noting that the residual block used to extract RR interval features, the convolution length as 1 × 1.

    LSTM layer: LSTM boasts a distinctive gate mechanism internally, endowing it with long-term memory capabilities and addressing concerns related to gradient vanishing and exploding [23]. Hence, following the concatenation of the extracted features, we employed LSTM to discern critical information among features, with the LSTM units set to 64.

    Fully connected layer: After learning the dependencies between sequences, we utilized a fully connected layer with 64 units and ReLU activation function for feature mapping. Subsequently, we concatenate the RR interval features with another fully connected layer containing 5 units to enhance its classification decision-making capability. Finally, we mapped the obtained 10 features to a fully connected layer with 4 units and utilized the softmax activation function to compute the probability of each class.

    In this paper, the experiment was conducted on a server with an NVIDIA GeForce RTX 3090 graphics card and Ubuntu 20.04 operating system. The loss function adopts dynamic weighted focal loss.

    The gradient descent optimizer uses the Adam optimizer [24] with a learning rate of 0.001. The batch size of ECG data is set to 16 in the multi-path parallel deep convolutional neural network.

    To evaluate the performance of the proposed method, we applied several widely used metrics. The detailed definitions are given as follows:

    accuracy=TP+TNTP+TN+FP+FN, (11)
    precision=TPTP+FP, (12)
    sensitivity=TPTP+FN, (13)
    specificity=TNFP+TN, (14)

    where TP is the number of positive samples predicted to be positive. TN is the number of negative samples predicted as negative. FN is the number of positive samples predicted as negative. FP is the number of negative samples predicted to be positive.

    Most of arrhythmia classification methods use the MIT-BIH ECG database as the research object. However, some researchers use only an intra-patient evaluation paradigm, neglecting the differences in ECG signals among individuals. In this paper, both intra-patient and inter-patient methods are used to evaluate the proposed method for ECG classification.

    In the intra-patient evaluation method, the training and testing sets involve non-repetitive random sampling of heartbeats from all patients. In the training and testing sets, there may be heartbeats of the same category from the same patient, and a 10-fold cross-validation method is used to evaluate the model's generalization ability. The 100,501 heartbeats in the DS1 + DS2 dataset were randomly shuffled and divided into 10 parts, with 9 parts ware used for model training, and 1 part was used for model testing. After repeating this process 10 times, the results of all model classification performances were aggregated. The resulting confusion matrix is presented in Table 4.

    Table 4.  Confusion matrix under the intra-patient assessment paradigm.
    N S V F
    N 88,464 555 238 118
    S 135 2603 13 0
    V 38 23 6850 55
    F 49 3 47 701

     | Show Table
    DownLoad: CSV

    From Table 5, compared with state-of-the-art methods using the intra-patient assessment paradigm, it can be found that the proposed method outperforms other methods in terms of classification performances, especially in the minority categories (S, V, F). Acharya et al. [10] achieved the best performance in the F category, because data augmentation method was used to generate the F samples. In the methods of Romdhane and Pr [26], Pandey and Janghel [27], and Shoughi and Dowlatshahi [28], these methods can get better performances in the N category than the proposed method. However, the sensitivities of the proposed method in the S, V, and F categories were larger than those of the other three methods, which has more important value in the clinical Arrhythmia Classification. According to the experimental results, it can be found that the weighted focal loss method can address the data imbalance problem effectively and improve the classification performances of the minority.

    Table 5.  Comparison of methods using the intra-patient assessment paradigm.
    Methods ACC N S V F Q
    % SEN PPV SPEC SEN PPV SPEC SEN PPV SPEC SEN PPV SPEC SEN PPV SPEC
    Acharya et al. [10] 94.03 91.54 87.43 96.71 90.59 94.30 98.63 94.22 95.30 98.84 96.06 94.76 98.67 97.75 98.73 99.69
    Kachuee et al. [25] 95.90 97.00 - - 89.00 - 96.00 - - 86.00 - - 98.00 - -
    Romdhane et al. [26] 98.41 99.49 98.96 - 77.88 87.65 - 94.54 95.73 - 82.10 83.65 - 98.51 99.31 -
    Pandey et al. [27] 98.58 99.54 99.44 - 92.00 91.02 - 95.81 96.80 - 80.55 85.22 - - - -
    Shoughi et al. [28] 98.71 99.01 99.60 98.01 92.74 82.82 99.58 97.35 94.57 99.63 83.33 87.50 99.91 99.75 98.54 99.88
    Proposed method 98.73 98.98 99.75 96.55 94.62 81.75 98.84 98.33 95.83 98.75 87.63 80.21 98.81 - - -

     | Show Table
    DownLoad: CSV

    In the inter-patient evaluation method, the training set and the testing set are divided based on different patients. The training set and testing set extracted by this method will be completely independent from different patients. Due to data imbalance and wave similarities between the N class and S class, the ECG classification becomes more challenging using inter-patient than using intra-patient assessment.

    Due to the difficulty of classification in the inter-patient evaluation method, most approaches only focus on the classification of normal beats (N), supraventricular ectopic beats (S), and ventricular ectopic beats (V), without considering the minority class of fusion beats (F). To compare other methods using this evaluation paradigm, we just consider for implementing classification experiments of N, S, and V. The confusion matrix resulting from the experiments is shown in Table 6.

    Table 6.  Confusion matrix under the inter-patient assessment paradigm.
    N S V
    N 40,042 2557 1286
    S 219 1510 93
    V 68 72 3056

     | Show Table
    DownLoad: CSV

    As shown in Table 7, compared with other methods, the proposed method achieves the best performances in the minority S and V classes, which can detect the abnormal ECG signals accurately. In terms of the overall accuracy, the methods proposed by Garcia et al. [29] and Siouda et al. [32] get slightly better results than the proposed method, because these methods achieve high sensitivity in the N category, resulting in overall good accuracy. However, these methods exhibit a high misdiagnosis rate for the S and V categories. In all, the proposed method can address the data imbalance and wave similarities between the N class and S class problem effectively, so as to improve the classification performances in the minorities, such as the S and V categories.

    Table 7.  Comparison of methods using the inter-patient assessment paradigm.
    Methods ACC N S V
    % SEN PPV SPEC SEN PPV SPEC SEN PPV SPEC
    Garcia et al. [29] 92.40 94.00 98.00 - 62.0 53.0 - 87.3 59.4 -
    Takalo-Mattila et al. [30] 89.92 91.89 97.00 - 62.49 55.86 - 89.23 50.89 -
    Li et al. [31] 88.99 94.54 93.33 80.08 35.22 65.88 98.83 88.35 79.86 94.92
    Siouda et al. [32] 93.11 99.14 93.78 - 13.27 69.41 - 56.13 82.57 -
    Proposed method 91.22 91.24 99.29 94.28 82.88 36.48 94.42 95.62 68.91 96.98

     | Show Table
    DownLoad: CSV

    To validate the effectiveness of the global average RR interval feature and the dynamic weighted Focal Loss function, we designed relevant ablation experiments in the inter-patient paradigm. The experiments utilized the global average RR interval feature, Focal Loss (FL), dynamic weighted Focal Loss function (DFL), and Cross-Entropy Loss function (CE) as experimental variables to investigate the ablation study. We conducted a total of six comparison experiments, denoted as: 1) Using CE loss function, 2) using global average RR interval feature with CE loss function, 3) using FL loss function, 4) using global average RR interval feature with FL loss function, 5) using FL loss function, and 6) using global average RR interval feature with DFL loss function.

    As shown in Table 8, when combining DFL and the global average RR interval features, the proposed method can solve the overfitting problem effectively caused by the imbalance between data and the similarity between N and S classes. Although in terms of overall accuracy, the proposed method is not the best one with 91.22%, smaller than the method with CE loss with 94.35%. Because N class accounts for 90.63% of the total training data, the network tends to overfit to N class, leading to a high accuracy rate for N class, which directly impacts the overall accuracy. However, it is not useful to help detect the abnormal ECG signals, resulting in a lower classification accuracy for S and V class.

    Table 8.  Evaluation indicators under different methods.
    Methods Class AVG SEN SEN PPV SPEC ACC
    CE FL DFL RR
    N 59.45 99.40 94.63 50.64 94.35
    S 0.55 17.24 99.90
    V 78.41 91.76 99.51
    N 72.29 96.54 97.01 73.99 93.43
    S 37.87 46.56 98.32
    V 82.45 71.37 97.69
    N 60.32 96.04 94.80 53.95 91.61
    S 4.28 4.84 96.74
    V 80.63 90.93 99.44
    N 89.79 91.08 99.16 93.22 91.02
    S 84.19 37.78 94.63
    V 94.09 66.34 96.66
    N 65.00 93.65 95.64 61.65 90.37
    S 10.54 8.01 93.46
    V 90.80 82.14 90.34
    N 89.91 91.24 99.29 94.28 91.22
    S 82.88 36.48 94.42
    V 95.62 68.91 96.98

     | Show Table
    DownLoad: CSV

    From Table 8, it can be found that the classification performances of S classes improve obviously using the global average RR interval features, which demonstrates that the global average RR interval features aid to distinguish between classes N and S effectively. When compared with CE loss function, it can be found that the FL and DFL can address data imbalance problem effectively with better classification accuracy. However, the parameter selection of FL method is a tricky problem by parameter sweeping. In contrast, the DFL can adjust the weight factors dynamically based on the number of different classes in the input without multiple experiments. When the FL method achieved the optimal wight factors, as [0.25, 8, 1], it can get approximate classification accuracy as DFL method. In contrast, the dynamic weighted focal loss (DFL) can effectively suppress the data imbalance problem and pay a key role to a few categories with larger weight factors.

    To better illustrate the advantages of DFL and RR intervals, we plotted the corresponding electrocardiograms as shown in Figure 3. In Figure 3(a), we can clearly observe that the waveforms of the N class and S class are highly similar, and the difference between the N class and S class is small. Therefore, during the classification task, without RR intervals, the network often finds it challenging to learn the differences between them. As shown in Figure 3(b), compared to the N class, the waveform of the V class tends to exhibit morphological abnormalities. However, due to data imbalance, the classification network is predominated by the N class. After using the DFL method, the proposed method can address the data imbalance effectively, so as to detect the V class.

    Figure 3.  Heartbeat display of different categories.

    To evaluate the impact of global average RR interval features on classification performance under different input conditions, we conducted relevant ablation experiments. As shown in Figure 2, we utilized two distinct input methods simultaneously for the global average RR interval features: 1) Extracting global average RR interval features using convolutional networks, and 2) concatenating global average RR interval features directly at the final fully connected layer. Consequently, we defined three experimental conditions: A1 without global average RR interval features; A2 with the global average RR interval features using convolutional networks; A3 with global average RR interval features directly at the final fully connected layer; and the proposed method used both the global average RR interval features.

    It can be seen from Table 9 that under different input methods, using the global average RR interval feature can improve the decision-making ability of the network. Using two input methods at the same time can significantly improve the sensitivity, accuracy, and specificity of the S-class classification. Therefore, using global average RR interval features can solve the problem of similarity between N-class and S-class data effectively.

    Table 9.  Evaluation metrics under different input methods.
    Methods ACC N S V
    % SEN PPV SPEC SEN PPV SPEC SEN PPV SPEC
    A1 90.37 93.65 95.64 61.65 10.54 8.01 93.46 90.80 82.14 90.34
    A2 89.31 91.02 97.17 76.56 39.74 19.67 93.72 93.96 73.23 97.60
    A3 84.46 86.41 96.10 69.37 24.97 7.58 88.22 91.58 84.96 98.87
    Proposed method 91.22 91.24 99.29 94.28 82.88 36.48 94.42 95.62 68.91 96.98

     | Show Table
    DownLoad: CSV

    In this paper, we propose a multi-path parallel deep convolutional neural network (MPP-CNN) and a dynamically weighted focal loss function for arrhythmia classification. In addition, the global average RR interval features are proposed to solve the problem of data similarity through two input methods. Furthermore, a dynamic weighted loss function has been developed to solve the imbalance problem by adjusting weights dynamically based on the proportion of each class in the input batch. Intra-patient and inter-patient experimental results show that the proposed method can achieve good classification performance, especially for the minority. In future work, the proposed method will be put into clinical diagnosis for arrhythmia classification.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    This work is supported in part by the National Key R & D Program of China (2023YFE0205600), the National Natural Science Foundation of China (62272415), the Key Research and Development Program of Zhejiang Province (2023C01041), and the Key Research and Development Program of Ningxia Province (2023BEG02065).

    Ling Xia is a guest editor for [Mathematical Biosciences and Engineering] and was not involved in the editorial review or the decision to publish this article. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.


    Acknowledgments



    The author acknowledges that many additional papers that could improve this review were not included in the reference list. The author is a senior researcher retired from the National Institute of Advanced Industrial Science and Technology, Japan (AIST). This research was privately conducted after the expiration of the contract period with AIST. The author expresses thanks to Mses. Yasuko Yamazaki, Ayako Sasaki (Library Group), and Drs. Shinya Honda, Kiyonori Hirota (Biomedical Research Institute) at AIST for helpful technical support and kind advice, respectively, about retrieving some of the reference papers. The author would like to gratefully appreciate Dr. Denise Blesila (Editage) for English language editing and also Ms. Keiko Muraki for her secretarial assistance.

    Conflict of interests



    The author declares that there is no conflict of interest.

    [1] McIlwain DR, Berger T, Mak TW (2013) Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 5: a008656. https://doi.org/10.1101/cshperspect.a008656
    [2] Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33: 29-55. https://doi.org/10.1146/annurev.genet.33.1.29
    [3] Pitti RM, Marsters SA, Lawrence DA, et al. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703. https://doi.org/10.1038/25387
    [4] Muraki M (2020) Sensitization to cell death induced by soluble Fas ligand and agonistic antibodies with exogenous agents: A review. AIMS Med Sci 7: 122-203. https://doi.org/10.3934/medsci.2020011
    [5] Cheng J, Zhou T, Liu C, et al. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762. https://doi.org/10.1126/science.7510905
    [6] Guégan JP, Legembre P (2018) Nonapoptotic functions of Fas/CD95 in the immune response. FEBS J 285: 809-827. https://doi.org/10.1111/febs.14292
    [7] Herrero R, Kajikawa O, Matute-Bello G, et al. (2011) The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region. J Clin Invest 121: 1174-1190. https://doi.org/10.1172/JCI43004
    [8] Malleter M, Tauzin S, Bessede A, et al. (2013) CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res 73: 6711-6721. https://doi.org/10.1158/0008-5472.CAN-13-1794
    [9] Holdenrieder S, Stieber P (2004) Apoptotic markers in cancer. Clin Biochem 37: 605-617. https://doi.org/10.1016/j.clinbiochem.2004.05.003
    [10] Audo R, Calmon-Hamaty F, Papon L, et al. (2014) Distinct effects of soluble and membrane-bound Fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheumatol 66: 3289-3299. https://doi.org/10.1002/art.38806
    [11] Hsieh SL, Lin WW (2017) Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. J Biomed Sci 24: 39. https://doi.org/10.1186/s12929-017-0347-7
    [12] Miwa K, Asano M, Horai R, et al. (1998) Caspase1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4: 1287-1297. https://doi.org/10.1038/3276
    [13] Kurma K, Boizard-Moracchini A, Galli G, et al. (2021) Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?. Biochim Biophys Acta Rev Cancer 1876: 188596. https://doi.org/10.1016/j.bbcan.2021.188596
    [14] Ueno T, Toi M, Tominaga T (1999) Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 5: 3529-3533.
    [15] Hara T, Tsurumi H, Takemura M, et al. (2000) Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 64: 257-261. https://doi.org/10.1002/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2
    [16] Konno R, Takao T, Sato S, et al. (2000) Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 6: 3576-3580.
    [17] Tsutsumi S, Kuwano H, Shimura T, et al. (2000) Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 89: 2560-2564. https://doi.org/10.1002/1097-0142(20001215)89:12<2560::AID-CNCR7>3.0.CO;2-Q
    [18] Mizutani Y, Hongo F, Sato N, et al. (2001) Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92: 287-293. https://doi.org/10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4
    [19] Ugurel S, Rappl G, Tilgen W, et al. (2001) Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7: 1282-1286.
    [20] Hoffmann TK, Dworacki G, Tsukihiro T, et al. (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck and its clinical importance. Clin Cancer Res 8: 2553-2562.
    [21] Akhmedkhanov A, Lundin E, Guller S, et al. (2003) Circulating soluble Fas levels and risk of ovarian cancer. BMC Cancer 3: 33. https://doi.org/10.1186/1471-2407-3-33
    [22] Sheen-Chen SM, Chen HS, Eng HL, et al. (2003) Circulating soluble Fas in patients with breast cancer. World J Surg 27: 10-13. https://doi.org/10.1007/s00268-002-6378-5
    [23] Wu Y, Han B, Sheng H, et al. (2003) Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 105: 724-732. https://doi.org/10.1002/ijc.11138
    [24] Erdoğan B, Uzaslan E, Budak F, et al. (2005) The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients. Tuberk Toraks 53: 127-131.
    [25] Nadal C, Maurel J, Gallego R, et al. (2005) Fas/Fas ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 11: 4770-4774. https://doi.org/10.1158/1078-0432.CCR-04-2119
    [26] Shimizu M, Kondo M, Ito Y, et al. (2005) Soluble Fas and Fas ligand new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detect Prev 29: 175-180. https://doi.org/10.1016/j.cdp.2004.09.001
    [27] Yatsuya H, Toyoshima H, Tamakoshi K, et al. (2005) Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study. J Epidemiol 15: S120-S125. https://doi.org/10.2188/jea.15.S120
    [28] Sonoda K, Miyamoto S, Hirakawa T, et al. (2006) Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol Oncol 103: 924-931. https://doi.org/10.1016/j.ygyno.2006.05.047
    [29] Svatek RS, Herman MP, Lotan Y, et al. (2006) Soluble Fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106: 1701-1707. https://doi.org/10.1002/cncr.21795
    [30] Baldini E, Ulisse S, Marchioni E, et al. (2007) Expression of Fas and Fas ligand in human testicular germ cell tumours. Int J Andorol 32: 123-130. https://doi.org/10.1111/j.1365-2605.2007.00823.x
    [31] Simon I, Liu Y, Krall KL, et al. (2007) Evaluation of the novel serum markers B7-H4, spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 106: 112-118. https://doi.org/10.1016/j.ygyno.2007.03.007
    [32] Aguilar-Lemarroy A, Romero-Ramos JE, Olimon-Andalon V, et al. (2008) Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer. BMC Cancer 8: 99. https://doi.org/10.1186/1471-2407-8-99
    [33] Chaudhry P, Srinvasan R, Patel FD, et al. (2008) Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int J Cancer 122: 1716-1721. https://doi.org/10.1002/ijc.23213
    [34] Connor JP, Felder M (2008) Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol 111: 330-335. https://doi.org/10.1016/j.ygyno.2008.07.012
    [35] Kilic A, Schubert MJ, Luketich JD, et al. (2008) Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. J Thorac Cardiovasc Surg 136: 199-204. https://doi.org/10.1016/j.jtcvs.2008.01.012
    [36] Macher-Goeppinger S, Aulmann S, Wagener N, et al. (2008) Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10: 1049-1056. https://doi.org/10.1593/neo.08626
    [37] Nolen BM, Marks JR, Ta'san S, et al. (2008) Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 10: R45. https://doi.org/10.1186/bcr2096
    [38] Tamakoshi A, Nakachi K, Ito Y, et al. (2008) Soluble Fas level and cancer mortality: Findings from a nested case-control study within a large-scale prospective study. Int J Cancer 123: 1913-1916. https://doi.org/10.1002/ijc.23731
    [39] Anderson GL, McIntosh M, Wu L, et al. (2010) Assessing lead time of selected ovarian cancer biomarkers: A nested case-control study. J Natl Cancer Inst 102: 26-38. https://doi.org/10.1093/jnci/djp438
    [40] Goon PKY, Lip GYH, Stonelake PS, et al. (2009) Circulating endothelial cells and circulating progenitor cells in breast cancer: Relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham prognostic index. Neoplasia 11: 771-779. https://doi.org/10.1593/neo.09490
    [41] Kavathia N, Jain A, Walston J, et al. (2009) Serum markers of apoptosis decrease with age and cancer stage. Aging 1: 652-663. https://doi.org/10.18632/aging.100069
    [42] Vysotskii MM, Digaeva MA, Kushlinskii NE, et al. (2009) Serum sFas, leptin, and VEGF in patients with ovarian cancer and benign tumors. Bull Exp Biol Med 148: 810-814. https://doi.org/10.1007/s10517-010-0823-5
    [43] Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, et al. (2010) Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer 10: 275. https://doi.org/10.1186/1471-2407-10-275
    [44] Habibagahi M, Jaberipour M, Fattahi MJ, et al. (2010) High concentration of serum soluble Fas in patients with head and neck carcinoma: A comparative study before and after surgical removal of tumor. Middle East J Cancer 1: 21-26.
    [45] Nolen B, Velikokhatnaya L, Marrangoni A, et al. (2010) Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117: 440-445. https://doi.org/10.1016/j.ygyno.2010.02.005
    [46] Ulukaya E, Acilan C, Yilmaz M, et al. (2010) sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients. Cell Biochem Funct 28: 565-570. https://doi.org/10.1002/cbf.1689
    [47] Yang M, Chen G, Dang Y, et al. (2010) Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Upsala J Med Sci 115: 232-237. https://doi.org/10.3109/03009734.2010.516410
    [48] Zekri AN, El-Din HMA, Bahnassy AA, et al. (2010) Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol 9: 1. https://doi.org/10.1186/1476-5926-9-1
    [49] Hoogwater FJH, Snoeren N, Nijkamp MW, et al. (2011) Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases. Anticancer Res 31: 4507-4512.
    [50] Fersching DMI, Nagel D, Siegele B, et al. (2012) Apoptosis-related biomarkers sFas, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. Anticancer Res 32: 2047-2058.
    [51] Hammam O, Mahmoud O, Zahran M, et al. (2012) The role of Fas/Fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma. Hepat Mon 12: e6132. https://doi.org/10.5812/hepatmon.6132
    [52] Izbicka E, Streeper RT, Michalek JE, et al. (2012) Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics 9: 27-35.
    [53] Eissa S, Swellam M, Abdel-Malak C, et al. (2013) The clinical relevance of urinary soluble fas (sFas) for diagnosis of bilharzial bladder cancer. Asian Biomed 7: 761-767. https://doi.org/10.5372/1905-7415.0706.238
    [54] Owonikoko TK, Hossain MS, Bhimani C, et al. (2013) Soluble Fas ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer 119: 1503-1511. https://doi.org/10.1002/cncr.27937
    [55] Elbedewy TA, El-Feky S, El Sheikh MA, et al. (2014) Serum levels of soluble Fas and soluble Fas ligand as markers for hepatocellular carcinoma in hepatitis C virus patients. Int J Adv Res 2: 911-919.
    [56] Xu Y, Zhang L, Sun S, et al. (2014) CC Chemokine ligand 18 and IGF-binding protein 6 as potential serum biomarkers for prostate cancer. Tohoku J Exp Med 233: 25-31. https://doi.org/10.1620/tjem.233.25
    [57] Yeh CN, Chung WH, Su SC, et al. (2014) Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction. J Invest Dermatol 134: 2768-2775. https://doi.org/10.1038/jid.2014.218
    [58] Kadam CY, Abhang SA (2015) Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer. Clin Chim Acta 438: 98-102. https://doi.org/10.1016/j.cca.2014.08.012
    [59] Kouloubnis A, Sofroniadou S, Panoulas VF, et al. (2015) The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines. IJC Heart Vasc 6: 85-90. https://doi.org/10.1016/j.ijcha.2015.01.002
    [60] Lancrajan I, Schneider-Stock R, Naschberger E, et al. (2015) Absolute quantification of DcR3 and GDF-15 from human serum by LC-ESI MS. J Cell Mol Med 19: 1656-1671. https://doi.org/10.1111/jcmm.12540
    [61] Bamias G, Gizis M, Delladetsima I, et al. (2016) Elevated serum levels of the antiapoptotic protein decoy-receptor 3 are associated with advanced liver disease. Can J Gastroenterol Hepatol 2016: 2637010. https://doi.org/10.1155/2016/2637010
    [62] Chang SW, Wang BC, Gong XG, et al. (2016) Serum decoy receptor 3 is a diagnostic and prognostic biomarker in patients with colorectal cancer. Int J Clin Exp Pathol 9: 7488-7492.
    [63] Dressen K, Hermann N, Manekeller S, et al. (2017) Diagnostic performance of a novel multiplex immunoassay in colorectal cancer. Anticancer Res 37: 2477-2486. https://doi.org/10.21873/anticanres.11588
    [64] Hermann N, Dressen K, Schroeder L, et al. (2017) Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer. Tumor Biol 2017: 1-11. https://doi.org/10.1177/1010428317711381
    [65] Johdi NA, Mazlan L, Sagap I, et al. (2017) Profiling of cytokines, chemokines and other soluble proteins as a potential biomarker in colorectal cancer and polyps. Cytokine 99: 35-42. https://doi.org/10.1016/j.cyto.2017.06.015
    [66] Li J, Xie N, Yuan J, et al. (2017) DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis. Oncotarget 8: 107612-107620. https://doi.org/10.18632/oncotarget.22544
    [67] Korczyński P, Mierzejewski M, Krenke R, et al. (2018) Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions. Pol Arch Intern Med 128: 354-361. https://doi.org/10.20452/pamw.4278
    [68] Ku SC, Ho PS, Tseng YT, et al. (2018) Benzodiazepine-associated carcinogenesis: Focus on lorazepam-associated cancer biomarker changes in overweight individuals. Psychiatry Invest 15: 900-906. https://doi.org/10.30773/pi.2018.05.02.1
    [69] Singh RK, Meena RN, Tiwary SK, et al. (2018) Fas ligand as a circulating apoptosis marker in carcinoma breast. World J Surg Res 7: 7-14.
    [70] Łaniewski P, Cui H, Roe DJ, et al. (2019) Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci Rep 9: 7333. https://doi.org/10.1038/s41598-019-43849-5
    [71] Wei Y, Chen X, Yang J, et al. (2019) DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. Am J Cancer Res 9: 2618-2633.
    [72] Akhmaltdinova L, Sirota V, Zhumaliyeva V, et al. (2020) Inflammatory serum biomarkers in colorectal cancer in Kazakhstan population. Int J Inflam 2020: 9476326. https://doi.org/10.1155/2020/9476326
    [73] Ali AS, Perren A, Lindskog C, et al. (2020) Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. Sci Rep 10: 10639. https://doi.org/10.1038/s41598-020-67670-7
    [74] Chiu CT, Wang PW, Asare-Werehene M, et al. (2020) Circulating plasma gelsolin: A predictor of favorable clinical outcomes in head and neck cancer and sensitive biomarker for early disease diagnosis combined with soluble Fas ligand. Cancers 12: 1569. https://doi.org/10.3390/cancers12061569
    [75] Feng K, Liu Y, Zhao Y, et al. (2020) Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer 8: e000367. https://doi.org/10.1136/jitc-2019-000367
    [76] Honma N, Inoue T, Tsuchiya N, et al. (2020) Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with axitinib. Health Sci Rep 3: e197. https://doi.org/10.1002/hsr2.197
    [77] Ghonaim E, El-Haggar S, Gohar S (2021) Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial. Med Oncol 38: 108. https://doi.org/10.1007/s12032-021-01558-y
    [78] López-Jornet P, Aznar C, Ceron J (2021) Salivary biomarkers in breast cancer: a cross-sectional study. Support Care Cancer 29: 889-896. https://doi.org/10.1007/s00520-020-05561-3
    [79] Jodo S, Kobayashi S, Kayagaki N, et al. (1997) Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107: 89-95. https://doi.org/10.1046/j.1365-2249.1997.d01-901.x
    [80] Ohtsuka K, Hashimoto M (2000) Serum levels of soluble Fas in patients with Graves' ophthalmopathy. Br J Ophthalmol 84: 103-106. https://doi.org/10.1136/bjo.84.1.103
    [81] Wang CY, Zhong WB, Chang TC, et al. (2002) Circulating soluble Fas ligand correlates with disease activity in Graves' Hyperthyroidism. Metabolism 51: 769-773. https://doi.org/10.1053/meta.2002.32034
    [82] Boku S, Takahashi T, Watanabe K, et al. (2003) Serum soluble Fas as a seromarker of disease activity in chronic hepatitis C and the possible involvement of peripheral blood mononuclear cells in the production of serum soluble Fas. Acta Med Biol 51: 49-58.
    [83] Kiraz S, Ertenli I, Öztürk MA, et al. (2003) Increased soluble Fas suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis. J Rheumatol 30: 313-315.
    [84] Silvestris F, Grinello D, Tucci M, et al. (2003) Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. Lupus 12: 8-14. https://doi.org/10.1191/0961203303lu250oa
    [85] Hayashi H, Maeda M, Murakami S, et al. (2009) Soluble interleukin-2 as an indicator of immunological disturbance found in silicosis patients. Int J Immunol Pharmacol 22: 53-62. https://doi.org/10.1177/039463200902200107
    [86] Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. (2009) FAS-L, IL-10, and double-negative CD4CD8 TCR α/β+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 113: 3027-3030. https://doi.org/10.1182/blood-2008-09-179630
    [87] Sahebari M, Hatef MR, Rezaieyazdi Z, et al. (2010) Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran. Arch Iran Med 13: 135-142. https://doi.org/10.1007/s00296-010-1633-9
    [88] Ikonomidis I, Tzortzis S, Lekakis J, et al. (2011) Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra. Thromb Haemost 106: 959-967. https://doi.org/10.1160/TH11-02-0117
    [89] Bamias G, Stamatelopoulos K, Zampeli E, et al. (2013) Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis. Clin Immunol 147: 144-150. https://doi.org/10.1016/j.clim.2013.03.002
    [90] Moreno M, Sáenz-Cuesta M, Castilló J, et al. (2013) Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. J Neuroimmunol 263: 152-154. https://doi.org/10.1016/j.jneuroim.2013.07.013
    [91] Oka S, Furukawa H, Shimada K, et al. (2013) Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease. BMC Immunol 14: 9. https://doi.org/10.1186/1471-2172-14-9
    [92] Rensing-Ehl A, Janda A, Lorenz MR, et al. (2013) Sequential decisions on Fas sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia. Heamatologica 98: 1948-1955. https://doi.org/10.3324/haematol.2012.081901
    [93] Roberts CA, Ayers L, Bateman EAL, et al. (2013) Investigation of common variable immunodeficiency patients and healthy individuals using autoimmune lymphoproliferative syndrome biomarkers. Hum Immunol 74: 1531-1535. https://doi.org/10.1016/j.humimm.2013.08.266
    [94] Bollain-y-Goytia JJ, Arellano-Rodríguez M, Torres-Del-Muro FJ, et al. (2014) Soluble Fas and the -670 polymorphism of Fas in lupus nephritis. Int J Nephrol 2014: 780406. https://doi.org/10.1155/2014/780406
    [95] Chen MH, Liu PC, Chang CW, et al. (2014) Decoy receptor 3 suppresses B cell functions and has a negative correlation with disease activity in rheumatoid arthritis. Clin Exp Rheumatol 32: 715-723.
    [96] Munroe ME, Vista ES, Guthridge JM, et al. (2014) Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 66: 1888-1899. https://doi.org/10.1002/art.38573
    [97] Price S, Shaw PA, Seitz A, et al. (2014) Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 123: 1989-1999. https://doi.org/10.1182/blood-2013-10-535393
    [98] Romano E, Terenzi R, Manetti M, et al. (2014) Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels. J Rheumatol 41: 1961-1965. https://doi.org/10.3899/jrheum.131544
    [99] Liu J, Zhao Z, Zou Y, et al. (2015) The expression of death decoy receptor 3 was increased in the patients with primary Sjögren's syndrome. Clin Rheumatol 34: 879-885. https://doi.org/10.1007/s10067-014-2853-2
    [100] Zijuan X, Hui S, Ye T, et al. (2015) Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis. Cytokine 72: 185-189. https://doi.org/10.1016/j.cyto.2014.12.026
    [101] Elsaeed GSM, Elshamaa MF, Salah DM, et al. (2016) Fas-ligand and granzyme-b levels in children with nephrotic syndrome. Int J Pharma Clin Res 8: 1600-1604.
    [102] Maruyama H, Hirayama K, Nagai M, et al. (2016) Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis. Clin Rheumatol 35: 2469-2476. https://doi.org/10.1007/s10067-016-3321-y
    [103] Chen MH, Kan HT, Liu CY, et al. (2017) Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients. J Formos Med Assoc 116: 49-56. https://doi.org/10.1016/j.jfma.2016.01.007
    [104] Engmann J, Rüdrich U, Behrens G, et al. (2017) Increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid. Acta Derm Venereol 97: 464-471. https://doi.org/10.2340/00015555-2581
    [105] Ding YW, Pan SY, Xie W, et al. (2018) Elevated soluble Fas and FasL in cerebrospinal fluid and serum of patients with anti-N-methyl-D-aspartate receptor encephalitis. Front Neurol 9: 904. https://doi.org/10.3389/fneur.2018.00904
    [106] Liphaus BL, Sallum AEM, Aikawa NE, et al. (2018) Increased soluble cytoplasmic Bcl-2 protein serum levels and expression and decreased Fas expression in lymphocytes and monocytes in Juvenile dermatomyositis. J Rheumatol 45: 1577-1580. https://doi.org/10.3899/jrheum.171248
    [107] Wigren M, Svenungsson E, Mattisson IY, et al. (2018) Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis. Atherosclerosis 270: 1-7. https://doi.org/10.1016/j.atherosclerosis.2018.01.022
    [108] Molnár E, Radwan N, Kovács G, et al. (2020) Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis. Blood 136: 1933-1945. https://doi.org/10.1182/blood.2020005486
    [109] Sremec J, Tomasović S, Sremec NT, et al. (2020) Elevated concentrations of soluble Fas and FasL in multiple sclerosis patients with antinuclear antibodies. J Clin Med 9: 3845. https://doi.org/10.3390/jcm9123845
    [110] Vincent FB, Kandane-Rathnayake R, Koelmeyer R, et al. (2020) Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. Lupus Sci Med 7: e000375. https://doi.org/10.1136/lupus-2019-000375
    [111] Kamal A, Abdelmegeid AK, Gabr MAM, et al. (2021) Serum decoy receptor 3 (DcR3): a promising biomarker for atopic asthma in children. Immunol Res 69: 568-575. https://doi.org/10.1007/s12026-021-09218-z
    [112] Kessel C, Fail N, Grom A, et al. (2021) Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. Lancet Rheumatol 3: 563-573. https://doi.org/10.1016/S2665-9913(21)00115-6
    [113] Qi Y, Xu J, Lin Z, et al. (2021) The network of pro-inflammatory factors CD147, DcR3, and IL33 in the development of Kawasaki disease. J Inflamm Res 14: 6043-6053. https://doi.org/10.2147/JIR.S338763
    [114] Su KW, Chiu CY, Tsai MH, et al. (2021) Cord blood soluble Fas ligand linked to allergic rhinitis and lung function in seven-year-old children. J Microbiol Immunol Infect . (in press). https://doi.org/10.1016/j.jmii.2021.03.016
    [115] De Freitas I, Fernández-Somoza M, Essenfeld-Sekler E, et al. (2004) Serum levels of the apoptosis-associated molecules, tumor necrosis factor-α/tumor necrosis factor type-I receptor and Fas/FasL, in sepsis. Chest 125: 2238-2246. https://doi.org/10.1378/chest.125.6.2238
    [116] Paunel-Görgülü A, Flohé S, Scholz M, et al. (2011) Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis. Crit Care 15: R20. https://doi.org/10.1186/cc9965
    [117] Hou YQ, Xu P, Zhang M, et al. (2012) Serum decoy receptor 3, a potential new biomarker for sepsis. Clin Chim Acta 413: 744-748. https://doi.org/10.1016/j.cca.2012.01.007
    [118] Huttunen R, Syrjänen J, Vuento R, et al. (2012) Apoptosis markers soluble Fas (sFas), Fas ligand (FasL) and sFas/sFasL ratio in patients with bacteremia: A prospective cohort study. J Infect 64: 276-281. https://doi.org/10.1016/j.jinf.2011.12.006
    [119] Kim S, Mi L, Zhang L (2012) Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis. Diagn Microbiol Infect Dis 73: 312-317. https://doi.org/10.1016/j.diagmicrobio.2012.04.008
    [120] Liu YJ, Shao LH, Wang Q, et al. (2014) Predictive value of decoy receptor 3 in postoperative nosocomial bacterial meningitis. Int J Mol Sci 15: 19962-19970. https://doi.org/10.3390/ijms151119962
    [121] Liu YJ, Shao LH, Zhang J, et al. (2015) The combination of decoy receptor 3 and soluble triggering receptor expressed on myeloid cells-1 for the diagnosis of nosocomial bacterial meningitis. Ann Clin Microbiol Antimicrob 14: 17. https://doi.org/10.1186/s12941-015-0078-0
    [122] Chu CM, Kao KC, Huang SH, et al. (2016) Diagnostic value of apoptosis biomarkers in severe sepsis-A pilot study. Cell Mol Biol 62: 32-37. https://doi.org/10.14715/cmb/2016.62.11.6
    [123] Carcillo JA, Halstead ES, Hall MW, et al. (2017) Three hypothetical inflammation pathobiology phenotypes and pediatric sepsis-induced multiple organ failure outcome. Pediatr Crit Care Med 18: 513-523. https://doi.org/10.1097/PCC.0000000000001122
    [124] Mikacenic C, Price BL, Harju-Baker S, et al. (2017) A two-biomarker model predicts mortality in the critically ill with sepsis. Am J Respir Crit Care Med 196: 1004-1011. https://doi.org/10.1164/rccm.201611-2307OC
    [125] Gao L, Yang B, Zhang H, et al. (2018) DcR3, a new biomarker for sepsis, correlates with infection severity and procalcitonin. Oncotarget 9: 10934-10944. https://doi.org/10.18632/oncotarget.23736
    [126] Garcia-Obregon S, Azkargorta M, Seijas I, et al. (2018) Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. J Microbiol Immunol Infect 51: 465-472. https://doi.org/10.1016/j.jmii.2016.12.002
    [127] Hou Y, Liang D, Liu Y, et al. (2018) Up-regulation of DcR3 in microbial toxins-stimulated HUVECs involves NF-κB signaling. BMC Biochem 19: 13. https://doi.org/10.1186/s12858-018-0102-z
    [128] Zhao JJ, Lou XL, Chen HW, et al. (2018) Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis. Cell Mol Biol Lett 23: 22. https://doi.org/10.1186/s11658-018-0087-z
    [129] Thompson K, Connor J (2019) When cultures fail: Postmortem decoy receptor 3 (DcR3) as a marker of antemortem sepsis. Acad Forensic Pathol 9: 15-23. https://doi.org/10.1177/1925362119851075
    [130] Hassan MH, Yassin MM, Hassan YM, et al. (2020) Decoy receptor 3 as a biomarker for diagnosis of bacterial sepsis. Egypt J Med Microbiol 29: 153-162. https://doi.org/10.51429/EJMM29320
    [131] Medina LMP, Rath E, Jahagirdar S, et al. (2021) Discriminatory plasma biomarkers predict specific clinical phenotypes of necrotizing soft-tissue infections. J Clin Invest 131: e149523. https://doi.org/10.1172/JCI149523
    [132] Iio S, Hayashi N, Mita E, et al. (1998) Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29: 517-523. https://doi.org/10.1016/S0168-8278(98)80145-1
    [133] Raghuraman S, Abraham P, Daniel HD, et al. (2005) Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection. J Clin Virol 34: 63-70. https://doi.org/10.1016/j.jcv.2005.01.009
    [134] Torre F, Bellis L, Delfino A, et al. (2008) Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness?. Digest Liver Dis 40: 441-445. https://doi.org/10.1016/j.dld.2007.10.027
    [135] Hou Y, Xu P, Lou X, et al. (2013) Serum decoy receptor 3 is a useful predictor for the active status of chronic hepatitis B in hepatitis B e antigen-negative patients. Tohoku J Exp Med 230: 227-232. https://doi.org/10.1620/tjem.230.227
    [136] Dong Y, Shi D, Li M, et al. (2015) Elevated serum levels of decoy receptor 3 are associated with disease severity in patients with hemorrhagic fever with renal syndrome. Intern Emerg Med 10: 567-573. https://doi.org/10.1007/s11739-015-1195-7
    [137] Lin YT, Yen CH, Chen HL, et al. (2015) The serologic decoy receptor 3 (DcR3) levels are associated with slower disease progression in HIV-1/AIDS patients. J Formos Med Assoc 114: 498-503. https://doi.org/10.1016/j.jfma.2013.01.007
    [138] Ikomey GM, Julius A, Jacobs GB, et al. (2016) Fas mediated (CD95L) peripheral T-cell apoptosis marker in monitoring HIV-1 disease progression in adults in Yaoundé, Cameroon. Int J Immunol 4: 1-5. https://doi.org/10.11648/j.iji.20160401.11
    [139] Ikomey G, Assoumou MCO, Atashili J, et al. (2016) The potentials of Fas receptors and ligands in monitoring HIV-1 disease in children in Yaoundé, Cameroon. J Int Assoc Prov AIDS Care 15: 418-422. https://doi.org/10.1177/2325957413488202
    [140] McElroy AK, Harmon JR, Flietstra TD, et al. (2016) Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. Clin Infect Dis 63: 460-467. https://doi.org/10.1093/cid/ciw334
    [141] Shin SY, Jeong SH, Sung PS, et al. (2016) Comparative analysis of liver injury-associated cytokines in acute hepatitis A and B. Yonsei Med J 57: 652-657. https://doi.org/10.3349/ymj.2016.57.3.652
    [142] Lou X, Hou Y, Cao H, et al. (2018) Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis. Oncol Lett 16: 1147-1154. https://doi.org/10.3892/ol.2018.8762
    [143] Zhang Z, Dai X, Qi J, et al. (2018) Astragalus mongholicus (Fisch.) Bge improves peripheral Treg cell immunity imbalance in the children with viral myocarditis by reducing the levels of miR-146b and miR-155. Front Pediatr 6: 139. https://doi.org/10.3389/fped.2018.00139
    [144] Dambaya B, Nkenfou CN, Ambada G, et al. (2019) Differential expression of Fas receptors (CD95) and Fas ligands (CD95L) in HIV infected and exposed uninfected children in Cameroon versus unexposed children. Pan Afric Med J 34: 39. https://doi.org/10.11604/pamj.2019.34.39.15038
    [145] Liang DY, Sha S, Yi Q, et al. (2019) Hepatitis B X protein upregulates decoy receptor 3 expression via the PI3K/NF-κB pathway. Cell Signal 62: 109346. https://doi.org/10.1016/j.cellsig.2019.109346
    [146] Shata MTM, Abdel-hameed EA, Rouster SD, et al. (2019) HBV and HIV/HBV infected patients have distinct immune exhaustion and apoptotic serum biomarker profiles. Pathog Immun 4: 39-65. https://doi.org/10.20411/pai.v4i1.267
    [147] Mercedes R, Brown J, Minard C, et al. (2020) A liver biopsy validation pilot study of shear wave elastography, APRI, FIB-4, and novel serum biomarkers for liver fibrosis staging in children with chronic viral hepatitis. Glob Pediatr Health 6: 1-8. https://doi.org/10.1177/2333794X20938931
    [148] Abers MS, Delmonte OM, Ricotta EE, et al. (2021) An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 6: e144455. https://doi.org/10.1172/jci.insight.144455
    [149] El-Mesery M, El-Mowafy M, Youssef LF, et al. (2021) Serum soluble fibrinogen-like protein 2 represents a novel biomarker for differentiation between acute and chronic Egyptian hepatitis B virus-infected patients. J Interferon Cytokine Res 41: 52-59. https://doi.org/10.1089/jir.2020.0118
    [150] Kessel C, Vollenberg R, Masjosthusmann K, et al. (2021) Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers. Arthritis Rheumatol 73: 1791-1799. https://doi.org/10.1002/art.41763
    [151] Armah HB, Wilson NO, Sarfo BY, et al. (2007) Cerebrospinal fluid and serum biomarkers of malaria mortality in Ghanaian children. Malar J 6: 147. https://doi.org/10.1186/1475-2875-6-147
    [152] Jain V, Armah HB, Tongren JE, et al. (2008) Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malar J 7: 83. https://doi.org/10.1186/1475-2875-7-83
    [153] Wu SH, Li CT, Lin CH, et al. (2010) Soluble Fas ligand is another good diagnostic marker for tuberculous pleurisy. Diagn Microbiol Infect Dis 68: 395-400. https://doi.org/10.1016/j.diagmicrobio.2010.08.008
    [154] Shu CC, Wu MF, Hsu CL, et al. (2013) Apoptosis-associated biomarkers in tuberculosis: promising for diagnosis and prognosis prediction. BMC Infect Dis 13: 45. https://doi.org/10.1186/1471-2334-13-45
    [155] Goeijenbier M, Gasem MH, Meijers JCM, et al. (2015) Markers of endothelial cell activation and immune activation are increased in patients with severe leptospirosis and associated with disease severity. J Infect 71: 437-446. https://doi.org/10.1016/j.jinf.2015.05.016
    [156] Shu CC, Wang JY, Hsu CL, et al. (2015) Diagnostic role of inflammatory and anti-inflammatory cytokines and effector molecules of cytotoxic T lymphocytes in tuberculous pleural effusion. Respirology 20: 147-154. https://doi.org/10.1111/resp.12414
    [157] Korczynski P, Klimiuk J, Safianowska A, et al. (2019) Impact of age on the diagnostic yield of four different biomarkers of tuberculous pleural effusion. Tuberculosis 114: 24-29. https://doi.org/10.1016/j.tube.2018.11.004
    [158] Struck NS, Zimmermann M, Krumkamp R, et al. (2020) Cytokine profile distinguishes children with Plasmodium falciparum malaria from those with bacterial blood stream infections. J Infect Dis 221: 1098-1106. https://doi.org/10.1093/infdis/jiz587
    [159] Nishigaki K, Minatoguchi S, Seishima M, et al. (1997) Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 29: 1214-1220. https://doi.org/10.1016/S0735-1097(97)00055-7
    [160] Sliwa K, Skudickey D, Bergemann A, et al. (2000) Peripartum cardiomyopathy: Analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 35: 701-705. https://doi.org/10.1016/S0735-1097(99)00624-5
    [161] Adamopoulos S, Parissis J, Karatzas D, et al. (2002) Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 39: 653-663. https://doi.org/10.1016/S0735-1097(01)01795-8
    [162] Shimizu M, Fukuo K, Nagata S, et al. (2002) Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 39: 585-590. https://doi.org/10.1016/S0735-1097(01)01800-9
    [163] Blanco-Colio LM, Martín-Ventura JL, Sol JM, et al. (2004) Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Normalization by atorvastatin. J Am Coll Cardiol 43: 1188-1194. https://doi.org/10.1016/j.jacc.2003.10.046
    [164] Van der Meer IM, Oei HHS, Hofman A, et al. (2006) Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam coronary calcification study. Atherosclerosis 189: 464-469. https://doi.org/10.1016/j.atherosclerosis.2006.01.004
    [165] Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al. (2007) Increased soluble Fas plasma levels in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 27: 168-174. https://doi.org/10.1161/01.ATV.0000250616.26308.d7
    [166] Blanco-Colio LM, Martín-Ventura JL, Tuñón J, et al. (2008) Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease. A novel biomarker of endothelial function?. Atherosclerosis 201: 407-412. https://doi.org/10.1016/j.atherosclerosis.2008.02.005
    [167] Boos CJ, Balakrishnan B, Blann AD, et al. (2008) The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: Implications for prognosis. J Thromb Haemost 6: 1841-1850. https://doi.org/10.1111/j.1538-7836.2008.03148.x
    [168] Lanfear DE, Hasan R, Gupta RC, et al. (2009) Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. J Trans Med 7: 67. https://doi.org/10.1186/1479-5876-7-67
    [169] Cardinal H, Brophy JM, Bogaty P, et al. (2010) Usefulness of soluble Fas levels for improving diagnostic accuracy and prognosis for acute coronary syndromes. Am J Cardiol 105: 797-803. https://doi.org/10.1016/j.amjcard.2009.10.061
    [170] Oyama JI, Maeda T, Sasaki M, et al. (2010) Green tea catechins improve human forearm vascular function and have potent anti-inflammatory and anti-apoptotic effects in smokers. Intern Med 49: 2553-2559. https://doi.org/10.2169/internalmedicine.49.4048
    [171] Cross DS, McCarty CA, Hytopoulos E, et al. (2012) Improved coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. Curr Med Res Opin 28: 1819-1830. https://doi.org/10.1185/03007995.2012.742878
    [172] Fertin M, Bauters A, Pinet F, et al. (2012) Circulating levels of soluble Fas ligand and left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). J Cardiol 60: 93-97. https://doi.org/10.1016/j.jjcc.2012.03.001
    [173] Kinugawa T, Kato M, Yamamoto K, et al. (2012) Proinflammatory cytokine activation is linked to apoptotic mediator; soluble Fas level in patients with chronic heart failure. Int Heart J 53: 182-186. https://doi.org/10.1536/ihj.53.182
    [174] Sahinarslan A, Boyaci B, Kocaman SA, et al. (2012) The relationship of serum soluble Fas ligand (sFasL) level with the extent of coronary artery disease. Int J Angiol 21: 29-34. https://doi.org/10.1055/s-0032-1306418
    [175] Nilsson L, Szymanowski A, Swahn E, et al. (2013) Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Plos One 8: e55477. https://doi.org/10.1371/journal.pone.0055477
    [176] Osmancik P, Teringova E, Tousek P, et al. (2013) Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. Plos One 8: e53860. https://doi.org/10.1371/journal.pone.0053860
    [177] Shah NR, Bieniarz MC, Basra SS, et al. (2013) Serum biomarkers in severe refractory cardiogenic shock. J Am Coll Cardiol HF 1: 200-206. https://doi.org/10.1016/j.jchf.2013.03.002
    [178] Szymanowski A, Li W, Lundberg A, et al. (2014) Soluble Fas ligand is associated with natural killer cell dynamics in coronary artery disease. Atherosclerosis 233: 616-622. https://doi.org/10.1016/j.atherosclerosis.2014.01.030
    [179] Taneja AK, Gaze D, Coats AJS, et al. (2014) Effects of nebivolol on biomarkers in elderly patients with heart failure. Int J Cardiol 175: 253-260. https://doi.org/10.1016/j.ijcard.2014.05.018
    [180] Chang TY, Hsu CY, Huang PH, et al. (2015) Usefulness of circulating decoy receptor 3 in predicting coronary artery disease severity and future major adverse cardiovascular events in patients with multivessel coronary artery disease. Am J Cardiol 116: 1028-1033. https://doi.org/10.1016/j.amjcard.2015.06.041
    [181] Adly AA, Ismail EA, Andrawes NG, et al. (2016) Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. Cytokine 79: 52-58. https://doi.org/10.1016/j.cyto.2015.12.022
    [182] Iso H, Maruyama K, Eshak ES, et al. (2017) Blood soluble Fas levels and mortality from cardiovascular disease in middle-aged Japanese: The JACC study. Atherosclerosis 260: 97-101. https://doi.org/10.1016/j.atherosclerosis.2017.03.020
    [183] Mattisson IY, Björkbacka H, Wigren M, et al. (2017) Elevated markers of death receptor-activated apoptosis are associated with increased risk for development of diabetes and cardiovascular disease. EBioMedicine 26: 187-197. https://doi.org/10.1016/j.ebiom.2017.11.023
    [184] Yan Y, Song D, Liu L, et al. (2017) The relationship of plasma decoy receptor 3 and coronary collateral circulation in patients with coronary artery disease. Life Sci 189: 84-88. https://doi.org/10.1016/j.lfs.2017.09.025
    [185] Li XY, Hou HT, Chen HX, et al. (2018) Increased circulating levels of tumor necrosis factor-like cytokine IA and decoy receptor 3 correlate with SYNTAX score in patients undergoing coronary surgery. J Int Med Res 46: 5167-5175. https://doi.org/10.1177/0300060518793787
    [186] Chen X, Wang R, Chen W, et al. (2019) Decoy receptor-3 regulates inflammation and apoptosis via PI3K/AKT signaling pathway in coronary heart disease. Exp Ther Med 17: 2614-2622. https://doi.org/10.3892/etm.2019.7222
    [187] Miyoshi T, Hosoda H, Nakai M, et al. (2019) Maternal biomarkers for fetal heart failure in fetuses with congenital heart defects or arrhythmias. Am J Obstet Gynecol 220: 104.e1-15. https://doi.org/10.1016/j.ajog.2018.09.024
    [188] Younus M, Fan W, Harrington DS, et al. (2019) Usefulness of a coronary artery disease predictive algorithm to predict global risk for cardiovascular disease and acute coronary syndrome. Am J Cardiol 123: 769-775. https://doi.org/10.1016/j.amjcard.2018.11.044
    [189] Doustkami H, Avesta L, Babapour B, et al. (2021) Correlation of serum decoy receptor 3 and interleukin-6 with severity of coronary artery diseases in male acute myocardial infarction patients. Acta Biomed 92: e2021285. https://doi.org/10.23750/abm.v92i5.9711
    [190] Masse M, Hérbert MJ, Troyanov S, et al. (2002) Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant 17: 485-491. https://doi.org/10.1093/ndt/17.3.485
    [191] El-Agroudy AE, El-Baz A (2010) Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients. Clin Exp Nephrol 14: 152-157. https://doi.org/10.1007/s10157-009-0261-8
    [192] Chang EP, Lin YS, Huang SC, et al. (2012) High serum DcR3 levels are associated with the occurrence of peritonitis in patients receiving chronic peritoneal dialysis. J Chin Med Assoc 75: 644-648. https://doi.org/10.1016/j.jcma.2012.09.009
    [193] Dounousi E, Koliousi E, Papagianni A, et al. (2012) Mononuclear leukocyte apoptosis and inflammatory markers in patients with chronic kidney disease. Am J Nephrol 36: 531-536. https://doi.org/10.1159/000345352
    [194] Hung SC, Hsu TW, Lin YP, et al. (2012) Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 7: 1257-1265. https://doi.org/10.2215/CJN.08410811
    [195] Bartnicki P, Rysz J, Franczyk B, et al. (2016) Impact of continuous erythropoietin receptor activator on selected biomarkers of cardiovascular disease and left ventricle structure and function in chronic kidney disease. Oxid Med Cell Longev 2016: 9879615. https://doi.org/10.1155/2016/9879615
    [196] Bhatraju PK, Robinson-Cohen C, Mikacenic C, et al. (2017) Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype. Critical Care 21: 217. https://doi.org/10.1186/s13054-017-1807-x
    [197] Claro LM, Moreno-Amaral AN, Gadotti AC, et al. (2018) The impact of uremic toxicity induced inflammatory response on the cardiovascular burden in chronic kidney disease. Toxins 10: 384. https://doi.org/10.3390/toxins10100384
    [198] Raptis V, Bakogiannis C, Loutradis C, et al. (2018) Serum Fas ligand, serum myostatin and urine TGF-β1 are elevated in autosomal dominant polycystic kidney disease patients with impaired and preserved renal function. Kidney Blood Press Res 43: 744-754. https://doi.org/10.1159/000489911
    [199] Bhatraju PK, Zelnick LR, Katz R, et al. (2019) A prediction model for severe AKI in critically ill adults that incorporates clinical and biomarker data. Clin J Am Soc Nephrol 14: 506-514. https://doi.org/10.2215/CJN.04100318
    [200] Chiloff DM, de Almeida DC, Dalboni MA, et al. (2020) Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease. Am J Physiol Renal Physiol 318: F861-F869. https://doi.org/10.1152/ajprenal.00433.2019
    [201] Abu-Rajab Tamimi TI, Elgouhari HM, Alkhouri N, et al. (2011) An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54: 1224-1229. https://doi.org/10.1016/j.jhep.2010.08.023
    [202] Fealy CE, Haus JM, Solomon TPJ, et al. (2012) Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol 113: 1-6. https://doi.org/10.1152/japplphysiol.00127.2012
    [203] Page S, Birerdinc A, Estep M, et al. (2013) Knowledge-based identification of soluble biomarkers: Hepatic fibrosis in NAFLD as an example. Plos One 8: e56009. https://doi.org/10.1371/journal.pone.0056009
    [204] El Bassat H, Ziada DH, Hasby EA, et al. (2014) Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis. Arab J Gastroenterol 15: 6-11. https://doi.org/10.1016/j.ajg.2014.01.009
    [205] Buck M, Garcia-Tsao G, Groszmann RJ, et al. (2014) Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology 59: 1052-1059. https://doi.org/10.1002/hep.26755
    [206] Alkhouri N, Alisi A, Okwu V, et al. (2015) Circulating soluble Fas and Fas ligand levels are elevated in children with nonalcoholic steatohepatitis. Dig Dis Sci 60: 2353-2359. https://doi.org/10.1007/s10620-015-3614-z
    [207] Ajmera V, Perito ER, Bass NM, et al. (2017) Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 65: 65-77. https://doi.org/10.1002/hep.28776
    [208] Perito ER, Ajmera V, Bass NM, et al. (2017) Association between cytokines and liver histology in children with nonalcoholic fatty liver disease. Hepatol Comm 1: 609-622. https://doi.org/10.1002/hep4.1068
    [209] Lin S, Wu B, Lin Y, et al. (2019) Expression and clinical significance of decoy receptor 3 in acute-on-chronic liver failure. BioMed Res Int 2019: 9145736. https://doi.org/10.1155/2019/9145736
    [210] Yasuda N, Gotoh K, Minatoguchi S, et al. (1998) An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 92: 993-999. https://doi.org/10.1016/S0954-6111(98)90343-2
    [211] Takabatake N, Arao T, Sata M, et al. (2005) Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD. Intern Med 44: 1137-1143. https://doi.org/10.2169/internalmedicine.44.1137
    [212] Chen CY, Yang KY, Chen MY, et al. (2009) Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med 180: 751-760. https://doi.org/10.1164/rccm.200902-0222OC
    [213] Carolan BJ, Hughes G, Morrow J, et al. (2014) The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res 15: 127. https://doi.org/10.1186/s12931-014-0127-9
    [214] Stapleton RD, Suratt BT, Neff MJ, et al. (2019) Bronchoalveolar fluid and plasma inflammatory biomarkers in contemporary ARDS patients. Biomarkers 24: 352-359. https://doi.org/10.1080/1354750X.2019.1581840
    [215] Aydin H, Tekin YK, Korkmaz I, et al. (2020) Apoptosis biomarkers (APAF-1, sFas, sFas-L, and caspase-9), albumin, and fetuin-A levels in pulmonary thromboembolic patients. Disaster Emerg Med J 5: 1-6. https://doi.org/10.5603/DEMJ.a2020.0005
    [216] Ghobadi H, Hosseini N, Aslani MR (2020) Correlations between serum decoy receptors 3 and airflow limitation and quality of life in male patients with stable stage and acute exacerbation of COPD. Lung 198: 515-523. https://doi.org/10.1007/s00408-020-00348-z
    [217] Felderhoff-Mueser U, Bührer C, Groneck P, et al. (2003) Soluble Fas (CD95/Apo-1), soluble Fas ligand, and activated caspase 3 in the cerebrospinal fluid of infants with posthemorrhagic and nonhemorrhagic hydrocephalus. Pediatr Res 54: 659-664. https://doi.org/10.1203/01.PDR.0000084114.83724.65
    [218] Sival DA, Felderhoff-Müser U, Schmitz T, et al. (2008) Neonatal high pressure hydrocephalus is associated with elevation of pro-inflammatory cytokines IL-18 and IFNγ in cerebrospinal fluid. Cerebrospinal Fluid Res 5: 21. https://doi.org/10.1186/1743-8454-5-21
    [219] Craig-Schapiro R, Kuhn M, Xiong C, et al. (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. Plos One 6: e18850. https://doi.org/10.1371/journal.pone.0018850
    [220] Leifsdottir K, Mehmet H, Eksborg S, et al. (2018) Fas-ligand and interleukin-6 in the cerebrospinal fluid are early predictors of hypoxic-ischemic encephalopathy and long-term outcomes after birth asphyxia in term infants. J Neuroinflammation 15: 223. https://doi.org/10.1186/s12974-018-1253-y
    [221] Jiang W, Jin P, Wei W, et al. (2020) Apoptosis in cerebrospinal fluid as outcome predictors in severe traumatic brain injury. An observational study. Medicine 99: e20922. https://doi.org/10.1097/MD.0000000000020922
    [222] Niewczas MA, Ficociello LH, Johnson AC, et al. (2009) Serum concentrations of markers of TNFα and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 4: 62-70. https://doi.org/10.2215/CJN.03010608
    [223] Hussian SK, Al-Karawi IN, Sahab KS (2013) Role of Fas/Fas ligand pathway in a sample of Iraqi diabetic foot patients. Diyala J Med 5: 95-107.
    [224] Stoynev N, Kainov K, Kirilov G, et al. (2014) Serum levels of sFas and sFasL in subjects with type 2 diabetes-the impact of arterial hypertension. Cent Eur J Med 9: 704-708. https://doi.org/10.2478/s11536-013-0318-7
    [225] Midena E, Micera A, Frizziero L, et al. (2019) Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema. Sci Rep 9: 10034. https://doi.org/10.1038/s41598-019-46515-y
    [226] Abe R, Shimizu T, Shibaki A, et al. (2003) Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162: 1515-1520. https://doi.org/10.1016/S0002-9440(10)64284-8
    [227] Stur K, Karlhofer FM, Stingl G, et al. (2007) Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 127: 802-807. https://doi.org/10.1038/sj.jid.5700648
    [228] Chung WH, Hung SI, Yang JY, et al. (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14: 1343-1350. https://doi.org/10.1038/nm.1884
    [229] Murata J, Abe R, Shimizu H (2008) Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 122: 992-1000. https://doi.org/10.1016/j.jaci.2008.06.013
    [230] Genç ŞÖ, Karakuş S, Çetin A, et al. (2019) Serum Bcl-2, caspase-9 and soluble FasL as perinatal markers in late preterm pregnancies with intrauterine growth restriction. Turk J Pediatr 61: 686-696. https://doi.org/10.24953/turkjped.2019.05.007
    [231] Yeh CC, Yang MJ, Lussier EC, et al. (2019) Low plasma levels of decoy receptor 3 (DcR3) in the third trimester of pregnancy with preeclampsia. Taiwan J Obstet Gynecol 58: 349-353. https://doi.org/10.1016/j.tjog.2019.03.011
    [232] Oyama JI, Yamamoto H, Maeda T, et al. (2012) Continuous positive airway pressure therapy improves vascular dysfunction and decreases oxidative stress in patients with the metabolic syndrome and obstructive sleep apnea syndrome. Clin Cardiol 35: 231-236. https://doi.org/10.1002/clc.21010
    [233] Chedraui P, Escobar GS, Pérez-López FR, et al. (2014) Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas 77: 370-374. https://doi.org/10.1016/j.maturitas.2014.01.014
    [234] Alkhouri N, Kheirandish-Gozal L, Matloob A, et al. (2015) Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea. Sleep Med 16: 1031-1035. https://doi.org/10.1016/j.sleep.2015.05.002
    [235] Farey JE, Fisher OM, Levert-Mignon AJ, et al. (2017) Decreased levels of circulating cancer-associated protein biomarkers following bariatric surgery. Obes Surg 27: 578-585. https://doi.org/10.1007/s11695-016-2321-y
    [236] Goto M (2008) Elevation of soluble Fas (APO-1, CD95) ligand in natural aging and Werner syndrome. BioSci Trend 2: 124-127.
    [237] Jiang S, Moriarty-Craige SE, Li C, et al. (2008) Associations of plasma-soluble Fas ligand with aging and age-related macular degeneration. Invest Ophthalmol Vis Sci 49: 1345-1349. https://doi.org/10.1167/iovs.07-0308
    [238] Karaflou M, Kaparos G, Rizos D, et al. (2010) Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women. Fertil Steril 94: 2399-2401. https://doi.org/10.1016/j.fertnstert.2010.04.010
    [239] Kämppä N, Mäkelä KM, Lyytikäinen LP, et al. (2013) Vascular cell adhesion molecule 1, soluble Fas and hepatocyte growth factor as predictors of mortality in nonagenarians: The vitality 90+ study. Exp Gerontrol 48: 1167-1172. https://doi.org/10.1016/j.exger.2013.07.009
    [240] Kangas R, Pöllänen E, Rippo MR, et al. (2014) Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy—a study with monozygotic twin pairs. Mech Ageing Dev 143–144: 1-8. https://doi.org/10.1016/j.mad.2014.11.001
    [241] Wu Q, Chen H, Fang J, et al. (2012) Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: A clinical analysis. Leuk Res 36: 275-280. https://doi.org/10.1016/j.leukres.2011.08.005
    [242] Fadel FI, Elshamaa MF, Salah A, et al. (2016) Fas/Fas ligand pathways gene polymorphisms in pediatric renal allograft rejection. Transpl Immunol 37: 28-34. https://doi.org/10.1016/j.trim.2016.04.006
    [243] Meki ARAM, Hasan HA, El-Deen ZMM, et al. (2003) Dysregulation of apoptosis in scorpion envenomed children: its reflection on their outcome. Toxicon 42: 229-237. https://doi.org/10.1016/S0041-0101(03)00128-4
    [244] Tamakoshi A, Suzuki K, Lin Y, et al. (2009) Cigarette smoking and serum soluble Fas levels: Findings from the JACC study. Mutat Res 679: 79-83. https://doi.org/10.1016/j.mrgentox.2009.08.002
    [245] Muraki M (2018) Development of expression systems for the production of recombinant human Fas ligand extracellular domain derivatives using Pichia pastoris and preparation of the conjugates by site-specific chemical modifications: A review. AIMS Bioengineer 5: 39-62. https://doi.org/10.3934/bioeng.2018.1.39
    [246] Muraki M, Hirota K (2019) Site-specific biotin-group conjugate of human Fas ligand extracellular domain: preparation and characterization of cell-death-inducing activity. Curr Top Pep Prot Res 20: 17-24.
    [247] Muraki M, Honda S (2010) Efficient production of human Fas receptor extracellular domain-human IgG1 heavy chain Fc domain fusion protein using baculovirus/silkworm expression system. Prot Expr Purif 73: 209-216. https://doi.org/10.1016/j.pep.2010.05.007
    [248] Connolly K, Cho YH, Duan R, et al. (2001) In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther 298: 25-33.
  • Reader Comments
  • © 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5542) PDF downloads(314) Cited by(4)

Figures and Tables

Figures(1)  /  Tables(6)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog